Olstein Capital Management L.P. Sells 22,000 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Olstein Capital Management L.P. cut its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 14.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 133,000 shares of the life sciences company’s stock after selling 22,000 shares during the quarter. Olstein Capital Management L.P. owned 0.17% of Integra LifeSciences worth $3,016,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Sachem Head Capital Management LP bought a new stake in shares of Integra LifeSciences in the 3rd quarter worth about $44,153,000. Glenmede Trust Co. NA increased its stake in Integra LifeSciences by 125.9% during the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock worth $13,224,000 after acquiring an additional 405,624 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in Integra LifeSciences by 64.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after purchasing an additional 335,557 shares during the period. Systematic Financial Management LP lifted its stake in shares of Integra LifeSciences by 540.6% in the 2nd quarter. Systematic Financial Management LP now owns 397,474 shares of the life sciences company’s stock valued at $11,582,000 after purchasing an additional 335,424 shares during the last quarter. Finally, Rubric Capital Management LP purchased a new position in shares of Integra LifeSciences in the 3rd quarter worth approximately $5,325,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Up 1.8 %

Shares of NASDAQ IART opened at $26.05 on Friday. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The business has a fifty day simple moving average of $23.32 and a two-hundred day simple moving average of $22.33. The firm has a market cap of $2.01 billion, a PE ratio of -289.41, a price-to-earnings-growth ratio of 0.83 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $380.80 million for the quarter, compared to analysts’ expectations of $375.81 million. During the same period in the prior year, the business earned $0.76 EPS. The firm’s quarterly revenue was down .4% on a year-over-year basis. Analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. The trade was a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Bank of America lowered their target price on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Truist Financial cut their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Finally, BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.